Technology

Marking the Course of Hepatitis B

It is a challenge to monitor the course of chronic hepatitis B. Patients still carry the Hepatitis B surface antigen (HBsAg) but have varying levels of viral DNA, HBeAg, and liver inflammation—and remain at risk for developing hepatocellular carcinoma (HCC). Two papers in this month’s issue of Gastroenterology investigate Hepatitis

Read more

New Word on GERD?

Proton pump inhibitors (PPIs) are useful for treating gastroesophageal reflux disease (GERD), although heartburn completely resolves in only 40% of patients that take these drugs. Furthermore, long-term use of PPIs can increase risk for pneumonia, Clostridium difficile infection, and bone disorders, so other therapeutic strategies are needed. In the August

Read more

Which Roads Lead to NASH?

Which Roads Lead to NASH? The progressive liver disease nonalcoholic steatohepatitis (NASH) is mediated by an innate immune response in the liver that causes tissue damage and fibrosis. The innate immune system protects against invading pathogens, but it’s not clear how it becomes activated in livers of patients with NASH.

Read more

Does Polyp Size Matter?

Computed tomography colonography (CTC) is a useful tool for colon cancer screening. The challenge, however, is determining which lesions are most dangerous—should some be treated aggressively and others just monitored or ignored? Does size matter? In the July issue of Clinical Gastroenterology and Hepatology, Perry Pickhardt et al. assessed the

Read more

Welcome to The AGA Journals Blog

Welcome to “The AGA Journals Blog”—a forum for discussion of the latest discoveries in the fields of gastroenterology and hepatology. Each week we will comment on a new article from the American Gastroenterological Association (AGA) journals Gastroenterology and Clinical Gastroenterology and Hepatology (CGH). The goals for the blog are two-fold:

Read more